BioCryst Pharmaceuticals, Inc. (BCRX) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate BioCryst Pharmaceuticals, Inc.'s investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
6.19
Strong
WeakModerateStrong
P/B Ratio
-13.74
Equity Deficit
Earnings Yield
16.12%
Strong
WeakModerateStrong
Profitability Health
2025Return on Equity
-221.45%
Weak
WeakModerateStrong
Operating Margin
38.98%
Strong
WeakModerateStrong
Net Profit Margin
30.16%
Strong
WeakModerateStrong
Growth Indicators
2025Revenue Growth
94.10%
Strong
WeakModerateStrong
Net Income Growth
396.87%
Strong
WeakModerateStrong
EPS Growth
393.02%
Strong
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
2.06
Strong
WeakModerateStrong
Quick Ratio
2.03
Strong
WeakModerateStrong
Asset Turnover
1.70x
Strong
WeakModerateStrong
Inventory Turnover
3.53x
Weak
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
20.00%
Strong
WeakModerateStrong
EV / Free Cash Flow
6.07x
Strong
WeakModerateStrong
Net Debt / EBITDA
1.00x
Moderate
WeakModerateStrong
Interest Burden (EBT / EBIT)
0.784
Weak
WeakModerateStrong
Return on Invested Capital
105.24%
Strong
WeakModerateStrong
Cash Conversion Cycle
-154.97 days
Strong
WeakModerateStrong
Fortress screener guardrails
4/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for BCRX.
View Financial Statements